The Indian Pharmaceutical Alliance (IPA) has stressed the importance of differentiating between spurious and sub-standard drugs, cautioning that linking counterfeit products with legitimate manufacturers can cause severe reputational and financial damage.This call to action follows a recent CDSCO report identifying over 50 products as ‘not of standard quality’. Leading pharmaceutical companies such as Sun Pharma and Glenmark refuted these claims, asserting their adherence to quality…
Read More…
Indian Pharma Urges Clear Distinction Between Spurious and Sub-Standard Drugs
